Physician profile
Cesar Tula
NPI 1487630885
$2,264.76
in general payments reported to CMS, 2019-2025
41 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.59 · 2020: $644 · 2021: $69.82 · 2022: $37.62 · 2023: $712 · 2024: $344 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.42 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $253.47 | 2020-2025 | Darzalex, Talvey, Erleada |
| Merck Sharp & Dohme LLC | $214.15 | 2020-2025 | Keytruda, Lynparza |
| Genzyme Corporation | $161.78 | 2020-2025 | |
| Dova Pharmaceuticals | $155.25 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $133.31 | 2019-2025 | Calquence, Enhertu |
| Incyte Corporation | $93.94 | 2020-2025 | Monjuvi, Zynyz, Jakafi |
| Legend Biotech USA INC. | $87.29 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $85.67 | 2023-2025 | Ojjaara, Arexvy, Shingrix |
| Tersera Therapeutics LLC | $77.73 | 2019-2024 | Xermelo |
| Karyopharm Therapeutics INC. | $69.76 | 2020-2024 | Xpovio |
| Eisai INC. | $61.63 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $57.39 | 2020-2025 | |
| Amgen INC. | $56.50 | 2020-2025 | Imlygic |
| Pfizer INC. | $55.85 | 2019-2023 | |
| Seagen INC. | $51.63 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Tula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.